Compare PLG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLG | KRRO |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.4M | 187.9M |
| IPO Year | 2002 | 2019 |
| Metric | PLG | KRRO |
|---|---|---|
| Price | $1.28 | $11.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | ★ 888.1K | 224.0K |
| Earning Date | 04-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $1.18 | $5.20 |
| 52 Week High | $4.04 | $55.89 |
| Indicator | PLG | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 37.08 |
| Support Level | $1.25 | $10.81 |
| Resistance Level | $1.48 | $14.53 |
| Average True Range (ATR) | 0.07 | 0.97 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 39.13 | 1.77 |
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.